Synthetic Biology Can Help Extend Anti-Malaria Drug Effectiveness

March 09, 2009

In addition to providing a simple and much less expensive means of making artemisinin, the most powerful anti-malaria drug in use today, synthetic biology can also help to extend the effectiveness of this drug. Fermenting artemisinin via engineered microbes, such as yeast, can be done at far lower costs than extracting the drug from Artemsisia annua, the sweet wormwood tree, making microbial-based artemisinin a much cheaper but equally effective treatment. Restricting access to this technology to responsible manufacturers who will bundle artemisinin as part of an anti-malarial drug "cocktail" rather than selling it as a monotherapy should delay or even prevent malaria parasites from developing resistance. Recently, there have been reports of malaria parasites in West Africa showing some signs of resistance to artemisinin.

"The problem has been that some manufacturers have sold artemisinin as a monotherapy rather than as a co-therapy as is recommended by the World Health Organization," said Jay Keasling, a chemical engineer with joint appointments at Berkeley Lab and UC Berkeley, who led the development of this microbial-based method of producing artemisinin. "Any drug that is used as a monotherapy raises the possibility of microbes developing resistance to it. Right now artemisinin is grown by farmers all over the world and sold to anybody. Through the synthetic biology technique, access to the cheapest artemisinin can be restricted to manufacturers who agree to sell it as part of a co-therapy drug."

Keasling, who is one of the world's leading researchers in synthetic biology and CEO of the Joint BioEnergy Institute (JBEI), one of three U.S. Department of Energy Bioenergy Research Centers, made his remarks at a press briefing at the annual meeting of the American Association for the Advancement of Science (AAAS). At the symposium on Synthetic Life, he gave a talk entitled: Synthetic Biology in Pursuit of Low-Cost, Effective, Anti-Malarial Drugs.

"Synthetic biology is somewhat like building a computer from the off-the-shelf parts," Keasling said in his talk. "You have a knowledge base, off-the-shelf components, a system for assembling these parts and an idea as to what you want to do."

For the microbial synthesis of artemisinin, the idea started with malaria, a disease first described in 4 B.C. by Hippocrates that continues to claim the lives of more than a million victims each year, most of them children. The complex life-cycle of Plasmodium falciparum, the parasite that carries malaria, makes it impossible to eradicate the disease. Treatment is the only option and the most effective current treatment is artemisinin, which releases high doses of oxygen-based free radicals that destroy the Plasmodium parasite while it is inside a red blood cell. The cost of extracting artemisinin from wormwood trees, which only produce the drug under a narrow set of agricultural and climatological conditions, or manufacturing it entirely through chemical synthesis, is so high that impoverished populations in Africa and South America who need it the most cannot afford it.

In 2002, Keasling and members of his research group, using the tools of synthetic biology, set out to engineer a microbe that would perform most of the chemistry needed to make artemisinin in order to substantially reduce production costs. In 2003, they reported their first success. By transplanting genes from yeast and from the sweet wormwood tree into E. coli bacteria and then by-passing the E. coli's metabolic pathway and engineering a new one based on the mevalonate pathway in yeast, they were able to induce the bacteria to produce amorphadiene, a chemical precursor to artemisinin.

"Initially production was low, but we have used gene re-synthesis and other techniques to improve the yield of amorphadiene in E. coli by a millionfold from where started," Keasling said.

In 2004, Keasling received a $42.6 million grant from the Bill and Melinda Gates Foundation, through the Institute for OneWorld Health, a San Francisco-based nonprofit pharmaceutical company, to further develop his microbial artemisinin technology. A bio-tech start-up company, Amyris Biotechnologies, Inc., which is based in Emeryville, licensed the technology. In 2006, the collaboration reported the use of synthetic biology techniques to genetically engineer a strain of yeast (Saccharomyces cerevisiae) that was capable of producing high levels of artemisinic acid, the immediate precursor to artemisinin.

"Given the existence of known, relatively high-yielding chemistry for converting artemisinic acid to artemisinin or any other derivative that might be desired, microbial produced artemisinic acid is a viable source of this potent family of anti-malarial drugs," said Keasling when the yeast breakthrough was first announced.

The engineering of the yeast was a three-step process in which Keasling and his group first created a new metabolic pathway in the yeast, similar to the one created in E. coli, then introduced bacterial and wormwood genes into the yeast's DNA that interacted with the yeast's own genes to produce amorphadiene. Finally, they cloned the gene from the wormwood tree that produces the enzyme P450, which the plant uses to convert amorphadiene to artemisinic acid, and expressed it in the amorphadiene-producing yeast strain.

"We got it right the first time we tried it," Keasling said at his AAAS talk. "This is not unprecedented in the literature but it is really memorable when it happens to you!."

Last year, Keasling and his collaborators formed a new partnership with Sanofi-aventis, a leading pharmaceutical company based in France, with the goal of mass-producing low-cost microbial-based artemisinin by 2010.

"Over the long run, we expect to be able to reduce the production costs by an order of magnitude, which will fulfill our goal of meeting and beating the current cost of plant-derived artemisinin," Keasling said. "The concept is to produce artemisinin cheaply and sell it to companies that will produce the right kinds of co-therapies and enable them to compete with companies that are trying to market artemisinin as a monotherapy."

Keasling said that the same synthetic biology techniques used to make the microbial-based artemisinin should be equally effective in the drive to produce a next generation of biofuels - carbon-neutral transportation fuels derived from plant biomass.

"Artemisinin is hydrocarbon and we built a microbial platform to produce it. We can remove a few of the genes to take out artemisinin and put in a different hydrocarbon to make biofuels."

As Keasling is fond of saying, "With the tools of synthetic biology, we don't have to just accept what Nature has given us."

For more information about the Joint BioEnergy Institute visit the website at http://www.jbei.org

For more information about OneWorld Health visit the Website at http://www.oneworldhealth.org

For more information about Amyris Biotechnologies, visit the Website at http://www.amyrisbiotech.com

Lawrence Berkeley National Laboratory

---

---

	The Use of the Herb Artemisinin for Babesia, Malaria, and Cancer: All the Practical Information You Need to Make Smart Decisions on Artemisinin by James Schaller (Author) This book is the only patient book written in English offering highly practical, clear, and carefully researched help on Artemisinin medications. Artemisinin herbals are powerful treatments for red blood cell infections like Malaria, and another red blood cell parasite called Babesia, which has at least eight species that infect humans and is often missed by physicians in the United States and all over the world.
	Artemisinins in Malaria Therapy by Qigui Li (Editor) This book presents an innovative assessment in the current and newer treatments of malaria therapy. Recently, a new class of antimalarial compounds has come to light which may assist in winning the battle with this ancient scourge. The artemisinins are antimalarials derived from the Chinese herb, Artemisia Annua. These compounds clear the parasites from the blood more rapidly than other antimalarial agents and have recently been recommended by the World Health Organisation as first line therapy in the fight against this age old killer. Intravenous formulations of artemisinins have been used in much of the world and represent an improvement in efficacy and safety for severe malaria. Much of this research data is used for the first time from databases at the Walter Reed Army Institute of...
	Artemisinin: Webster's Timeline History, 1891 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Artemisinin," including when used in literature (e.g. all authors that might have Artemisinin in their name). As such, this book represents the largest compilation of timeline events associated with Artemisinin when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...
	Antimalarial Drugs: Age of the Artemisinins (Pharmacology-Research Safety Testing and Regulation) by Qigui Li (Author), Peter J. Weina (Author) Antimalarial drugs are medicines that prevent or treat malaria, a disease which takes a great toll on human health and well-being, particularly in tropical regions including Africa south of the Sahara, South and Southeast Asia, Oceania, and parts of the Americas. In recent years, strains of Plasmodium have become increasingly resistant to more antimalarial drugs and researchers have stepped up efforts to revise antimalarial drug policies and develop new antimalarial strategies. Resistance has arisen to all classes of antimalarial (chloroquine, amodiaquine, mefloquine and sulfadoxine-pyrimethamine) except, as yet, definitively to the artemisinin derivatives. In order to prevent widespread resistance, the concept of antimalarial combination therapy (CT) has been employed and a global...
	Artemisinin, Artesunate, Artemisinic Acid and Other Derivatives of Artemisia Used for Malaria, Babesia and Cancer by James Schaller (Author) Dr. Schaller is the author of 15 books and has published on herbal medicine in the Journal of the American Medical Association. This book is the most up-to-date health care practitioner's guide on Artemisia medications. It offers detailed information on dosing, side effects, toxicity, effectiveness and other important prescribing data. Artemisinin herbals are powerful treatments for red blood cell infections like Malaria, and another red blood cell parasite called Babesia, which is often missed by physicians in the United States and all over the world. Like Malaria, Babesia causes intermittent flu-like fevers, sweats, significant fatigue, migraines, shortness of breath, and chest pain. Dr. Schaller has discovered that at least eight species of Babesia in America infect humans, and are the...
	An effective method for fast determination of artemisinin in Artemisia annua L. by high performance liquid chromatography with evaporative light ... [An article from: Analytica Chimica Acta] by C.Z. Liu (Author), H.Y. Zhou (Author), Y. Zhao (Author) This digital document is a journal article from Analytica Chimica Acta, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Artemisinin isolated from the aerial parts of Artemisia annua L., is a promising and potent antimalarial drug, which meets the dual challenge posed by drug-resistant parasites and rapid progression of malarial illness. The aim of the current study was to develop a reliable and fast analytical procedure for the determination of artemisinin in A. annua using high performance liquid chromatography (HPLC) with evaporative light scattering detection (ELSD) in couple with microwave-assisted extraction (MAE) as an...
	On-line conversion and determination of artemisinin and its kinetic parameters using orthogonal design by coupling of flow injection with capillary ... [An article from: Analytica Chimica Acta] by Y.Q. Cheng (Author), H.L. Chen (Author), L.Y. Fan (Author), X.G. Chen (Author), Z. Hu (Author) This digital document is a journal article from Analytica Chimica Acta, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: A rapid, accurate and improved capillary electrophoresis (CE) coupled with flow injection (FI) method with 6.5cm long separation capillary for the determination of artemisinin and its relevant kinetic parameters by on-line treatment with alkali has been developed. Orthogonal experimental design has been utilized to optimize experimental factors that affect the analysis of artemisinin. The buffer pH value (pH), the concentration of the buffer (C"N"a"""3"P"O"""4), the applied voltage (V"a), the concentration of...
	Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells.(Report): An article from: Phytomedicine: ... Journal of Phytotherapy & Phytopharmacology by Tan Weifeng (Author), Shen Feng (Author), Luo Xiangji (Author), Su Changqing (Author), Qiu Zhiquan (Author), Zeng Huazhong (Author), Yan Peining (Author), Yu Yong (Author), Wu Mengchao (Author), Jiang Xiaoqing (Author), Lau Wan-yee (Author) This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on January 15, 2011. The length of the article is 4175 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells.(Report) Author: Tan Weifeng Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Magazine/Journal) Date: January 15, 2011 Publisher: Urban & Fischer Verlag Volume: 18 Issue: 2-3 Page: 158(5) Article...
	EFFECT OF ARTEMISININ DERIVATIVES TO PLASMODIUM PINOTTII: Effect of some Artemisinin derivative antimalarial drugs to Bird Malaria, Plasmodium pinottii by SUNITA KANIKARAM (Author) Malaria is a dreadful disease of the tropics. The malarial parasite developed resistance to all the traditional antimalarial drugs till now. In recent years, from a Chinese plant Artemisia annua, artemisinin derivatives were synthesized which are potential antimalarial drugs. The present work aims at understanding the effect of Artemisinin derivatives Artemether and Arteether which are potential schizonticidal antimalarial drugs. The haemoglobin content, RBC count, serum Albumin and plaque levels were decreased during infectious condition. But WBC count and neutrophilic count were increased during infection of malaria. However after treatment these levels have become normal. Malaria prophylaxis was also studied with these drugs. Finally, malaria protection was observed and these drugs can...
	Use of Radiolytically Derived Oligomers for Artemisinin Production: Artemisia annua L. by Tariq Aftab (Author), M. Masroor A. Khan (Author) Malaria is thought to be among the oldest of human diseases. It has long had serious effects on morbidity and mortality, and in turn on the economic and social fabric of nations and society. Various methods have long been utilized to mitigate its frequency and effects in both temperate and tropical climates. Presently the most effective treatment of malaria is based on derivatives of artemisinin, an extract from the plant Artemisia annua. Only artemisinin-based combination therapies (ACTs) meets international standards set-up by WHO and UNICEF for the cure of malaria. The present demand for artemisinin is far more than that of supply, therefore, researchers are working round the world towards improving artemisinin content in the plant by various means. This work explains...